Hereditary Spastic Paraplegia (HSP)

🧠 Standard of Care & Symptoms

Hereditary Spastic Paraplegia (HSP), also known as Familial Spastic Paraplegia, is a heterogeneous group of inherited neurodegenerative disorders characterized by slowly progressive spasticity and weakness of the lower limbs.

• Presentation: Key features.
  • *Lower Limb Spasticity:* Muscle stiffness and tightness in the legs, leading to restricted range of motion, joint contractures, and gait difficulties (e.g. scissoring gait or toe walking).
  • *Weakness:* Symmetrical muscle weakness, most prominent in the iliopsoas, hamstrings, and tibialis anterior muscles.
  • *Hyperreflexia:* Overactive tendon reflexes in the lower limbs, often accompanied by clonus and positive Babinski signs.
  • *Sensory & Bladder Loss:* Mild impairment of vibration sensation in the feet and urinary urgency or frequency (neurogenic bladder).

🧬 Diagnostics & Axonal Pathophysiology

Diagnosis is based on clinical features, family history, brain/spinal cord MRI to exclude other causes, and genetic testing.

• Diagnostic Markers: Key criteria.
  • Genetic Sequencing panels: The gold standard. Deployed to detect mutations in known *SPG* genes. Autosomal dominant, recessive, and X-linked patterns are identified.
  • Brain & Spine MRI: Primarily used to rule out secondary causes (e.g. cervical myelopathy, Multiple Sclerosis). In complex forms, MRI may show spinal cord atrophy or a thin corpus callosum.
  • Motor Evoked Potentials (MEP): Electrophysiology showing prolonged central motor conduction times to the lower limbs, indicating corticospinal tract dysfunction.

Pathophysiology of Corticospinal Axonal Degeneration

HSP is characterized by selective retrograde degeneration of the longest axons in the central nervous system:

• SPG4 (Spastin Mutation): The most common form of autosomal dominant HSP (~40% of cases) is **SPG4**, caused by mutations in the **SPAST** gene. *SPAST* encodes **spastin**, a AAA ATPase protein that cuts and dynamics microtubules. Impaired spastin function causes microtubule instability, blocking axonal transport of proteins and organelles.
• Other Key Mutations: SPG3A (**ATL1**, encoding atlastin-1) and SPG31 (**REEP1**, encoding receptor expression-enhancing protein 1) are also common. Atlastin-1 and REEP1 are involved in formatting the tubular network of the endoplasmic reticulum (ER), which is crucial for lipid synthesis and ER distribution in long axons.
• Axon Length Vulnerability: The longest upper motor neuron axons projecting from the motor cortex to the lumbar spinal cord are selectively vulnerable due to high metabolic demand and dependence on axonal transport over long distances.

💊 Symptom Management & Spasticity Control

No disease-modifying therapies are currently approved. Management is symptomatic, focused on reducing lower limb spasticity and maintaining mobility.

Spasticity Pharmacotherapy

• Oral Muscle Relaxants: Oral **Baclofen** (GABA-B agonist) and **Tizanidine** (alpha-2 agonist) are first-line agents to reduce muscle tone. Doses are titrated to maximize stiffness reduction without causing excessive weakness or drowsiness.
• Local Injections: Botulinum toxin (Botox) injections into spastic muscles (e.g. gastrocnemius, adductors) are highly effective to relieve localized spasticity and improve gait.

Physical Therapy & Orthoses

• Physical & Occupational Therapy: Daily stretching and range-of-motion exercises are mandatory to prevent muscle contractures. Strength and balance training help maintain walking ability.
• Ankle-Foot Orthoses (AFOs): Custom braces are prescribed to correct foot drop and stabilize the ankle, reducing the risk of tripping and falls.

🔬 Active Clinical Trials

Clinical trials are currently evaluating gene replacement therapies, microtubule-stabilizing compounds, and advanced mobility assist systems.

🗺️ Next Steps After Diagnosis

If you have recently been diagnosed with Hereditary Spastic Paraplegia, establish these clinical care pathways:

1. Undergo Genetic Consultation: Identify the specific SPG genetic subtype to understand inheritance patterns and qualify for future gene-specific trials.
2. Establish a Physical Therapy Plan: Initiate a structured daily stretching routine to manage spasticity and prevent contractures.
3. Consult an Orthotist: Get evaluated for custom ankle-foot orthoses (AFOs) to improve walking safety.
4. Schedule a Urological Evaluation: Discuss bladder management strategies if experiencing urinary frequency or urgency.

❓ Patient FAQ

Q: What is the difference between "pure" and "complex" HSP?
A: "Pure" HSP is characterized by progressive lower limb spasticity, weakness, and minor sensory/bladder dysfunction. "Complex" HSP includes additional neurological features, such as peripheral neuropathy, ataxia, cognitive impairment, optic atrophy, or seizures.

Q: Is Hereditary Spastic Paraplegia the same as ALS or MS?
A: No. While all three involve upper motor neuron degeneration, they are distinct. MS is an autoimmune demyelinating disease. ALS is a rapid, progressive disease affecting both upper and lower motor neurons. HSP is a genetic, slow-progressing condition that selectively affects the longest axon tracts in the spinal cord.